or Try an Advanced Search...

    Technical Analysis for JANX - Janux Therapeutics, Inc.

    Grade Last Price % Change Price Change
    B 47.47 0.79% 0.37
    JANX closed down 2.3 percent on Thursday, April 25, 2024, on 48 percent of normal volume.
    Earnings due: May 10
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Down
    Historical JANX trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.79%
    MACD Bearish Signal Line Cross Bearish -1.53%
    Multiple of Ten Bearish Other -1.53%
    Wide Bands Range Expansion -1.53%
    Multiple of Ten Bearish Other -4.64%
    Wide Bands Range Expansion -4.64%
    Hammer Candlestick Bullish -2.88%
    1,2,3 Pullback Bullish Bullish Swing Setup -2.88%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -2.88%
    Pocket Pivot Bullish Swing Setup -2.88%
    Older End-of-Day Signals for JANX ...

       Recent Intraday Alerts

    Alert Time
    Up 2% 10 minutes ago
    Up 1% 10 minutes ago
    60 Minute Opening Range Breakdown about 23 hours ago
    Down 5% about 23 hours ago
    Down 3% 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    JANX Chart by TradingView
    Basic chart:

    Profile

    Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunology Immune System Tumor Platform Technology Chimeric Antigen Receptor T Cell T Cell Clusters Of Differentiation

    Is JANX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 17 Take the Money and Run: 3 Overbought Stocks to Sell ASAP
    Apr 16 Janux a new buy at Jones on lead assets for solid tumors
    Apr 16 These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
    Apr 15 Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors
    Apr 12 Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainable
    Apr 12 Why Janux Therapeutics Stock Is Crushing It This Week
    Apr 11 Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday?
    Apr 11 Wall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a Bet
    Apr 11 Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
    Apr 11 Janux Therapeutics: A Prime Target In Cancer Care's M&A Game
    See more JANX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 58.6936
    52 Week Low 5.65
    Average Volume 1,148,616
    200-Day Moving Average 16.87
    50-Day Moving Average 37.81
    20-Day Moving Average 44.29
    10-Day Moving Average 49.45
    Average True Range 3.73
    RSI (14) 59.35
    ADX 39.85
    +DI 24.85
    -DI 17.19
    Chandelier Exit (Long, 3 ATRs) 45.09
    Chandelier Exit (Short, 3 ATRs) 45.81
    Upper Bollinger Bands 56.64
    Lower Bollinger Band 31.95
    Percent B (%b) 0.61
    BandWidth 55.75
    MACD Line 3.54
    MACD Signal Line 3.84
    MACD Histogram -0.2986
    Fundamentals Value
    Market Cap 2.17 Billion
    Num Shares 46.2 Million
    EPS -1.47
    Price-to-Earnings (P/E) Ratio -32.04
    Price-to-Sales 51.42
    Price-to-Book 1.22
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 51.03
    Resistance 3 (R3) 50.99 49.65 50.38
    Resistance 2 (R2) 49.65 48.65 49.67 50.16
    Resistance 1 (R1) 48.37 48.03 47.70 48.41 49.94
    Pivot Point 47.03 47.03 46.69 47.05 47.03
    Support 1 (S1) 45.75 46.03 45.08 45.79 44.26
    Support 2 (S2) 44.41 45.41 44.43 44.04
    Support 3 (S3) 43.13 44.41 43.83
    Support 4 (S4) 43.17